Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors

Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors Am J Cardiovasc Drugs (2018) 18:103–108 https://doi.org/10.1007/s40256-017-0246-z ORIGINAL RESEARCH ARTICLE Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors 1 1 1 2 • • • • Pallavi B. Rane Jeetvan Patel David J. Harrison Jason Shepherd 2 2 2 • • Andrea Leith Hollie Bailey James Piercy Published online: 28 August 2017 Springer International Publishing AG 2017 Abstract use was reported in 69.1% of PCSK9i patients and 19.5% Background Proprotein convertase subtilisin/kexin type 9 of non-PCSK9i patients, and physician-reported statin inhibitors (PCSK9i) reduce low-density lipoprotein choles- intolerance was observed in 31.6% of PCSK9i and 5.3% of terol (LDL-C) levels and are approved for patients with non-PCSK9i patients. Use of statins only was reported in familial hypercholesterolemia or atherosclerotic cardiovas- 40.5% of PCSK9i and 88.8% of non-PCSK9i patients. The cular disease who require additional LDL-C lowering. most common physician-reported reasons for change to Objective Our objective was to characterize patients PCSK9i were lack of efficacy (70.2%) and muscle-related receiving PCSK9i medications in real-world practice and symptoms (myalgia 28.6%; myopathy 11.1%). describe physician-reported treatment patterns among Conclusions Physicians surveyed appeared to prescribe dyslipidemia patients using PCSK9i or other lipid-lowering PCSK9i medications appropriately. PCSK9i-treated therapy. patients had higher http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors

Loading next page...
 
/lp/springer_journal/patient-characteristics-and-real-world-treatment-patterns-among-early-Re2alQOVgz
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
D.O.I.
10.1007/s40256-017-0246-z
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs (2018) 18:103–108 https://doi.org/10.1007/s40256-017-0246-z ORIGINAL RESEARCH ARTICLE Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors 1 1 1 2 • • • • Pallavi B. Rane Jeetvan Patel David J. Harrison Jason Shepherd 2 2 2 • • Andrea Leith Hollie Bailey James Piercy Published online: 28 August 2017 Springer International Publishing AG 2017 Abstract use was reported in 69.1% of PCSK9i patients and 19.5% Background Proprotein convertase subtilisin/kexin type 9 of non-PCSK9i patients, and physician-reported statin inhibitors (PCSK9i) reduce low-density lipoprotein choles- intolerance was observed in 31.6% of PCSK9i and 5.3% of terol (LDL-C) levels and are approved for patients with non-PCSK9i patients. Use of statins only was reported in familial hypercholesterolemia or atherosclerotic cardiovas- 40.5% of PCSK9i and 88.8% of non-PCSK9i patients. The cular disease who require additional LDL-C lowering. most common physician-reported reasons for change to Objective Our objective was to characterize patients PCSK9i were lack of efficacy (70.2%) and muscle-related receiving PCSK9i medications in real-world practice and symptoms (myalgia 28.6%; myopathy 11.1%). describe physician-reported treatment patterns among Conclusions Physicians surveyed appeared to prescribe dyslipidemia patients using PCSK9i or other lipid-lowering PCSK9i medications appropriately. PCSK9i-treated therapy. patients had higher

Journal

American Journal of Cardiovascular DrugsSpringer Journals

Published: Aug 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off